Sedonase injection contains a highly purified streptokinase derived from
cultural filtrate of beta-hemolytic streptococci of lance
field group C.
The drug is supplied as a sterile, lyophilized white powder
Each vial contains: streptokinase BP 1,500,000 or 750.000 I.U.
Properties:
►Acute
myocardial infarction.
►Deep vein
thrombosis
►Pulmonary
embolism
►Acute or
sub-acute thrombosis of peripheral arteries
►Chronic
occlusive arterial disease
►Occlusion of
central retina artery or vein.
Indications:
►Acute
myocardial infarction :
(IV administration) in acute myocardial
infarction 1.5 million I.U of streptokinase
are infused in 60 min. with this regimen
usually no coagulation tests are necessary
to monitor streptokinase therapy.
Treatment should be started as soon as
possible after the onset of symptoms.
Significant reduction in mortality has been
observed with the administration of
streptokinase up to 24 hrs after onset of
symptoms.
However the earlier the treatment is started
the greater the clinical benefit will be in
terms of mortality reduction.
►Intracoronary
administration: A loading dose of 20,000 I.U,
streptokinase is given as a bolus, followed
by a 30 – 90 min infusion of 2000-4000
IU/min
►Deep vein
thrombosis, pulmonary embolism and other
indications : Streptokinase treatment should be
instituted as soon as possible after the
thrombotic event. Streptokinase therapy is
unlikely to be beneficial if instituted
►In more than
14 days after the onset of deep venous
thrombosis
►6 -8 hours
after onset of central retinal artery
occlusion.
►10 days from
onset of central retinal vein thrombosis
►6 weeks in
chronic arterial occlusions
►An initial
dose of 250,000 I.U streptokinase, by
intravenous infusion over a period of 30 min
is given. Followed by a maintenance dose of
100,000 I.U per hour for 24 to 72 hrs,
depending on the response.
►Heparin
should not be reinstituted during or
following streptokinase infusion until the
TT or APTT have reached less than twice or
1.5 times the normal control value
respectively.
